Regional Analysis
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
Global Anti-epileptic Drugs for Pediatrics Market Regional Insights
- North America is expected to account for the largest market share in the anti-epileptic drugs for pediatrics market during the forecast period, accounting for over 41.3% of the market share in 2023. The growth of the market in North America is due to the high prevalence of epilepsy, favorable reimbursements, and the presence of key players.
- Europe is expected to be the second-largest region for the anti-epileptic drugs for pediatrics market, accounting for over 23.1% of the market share in 2023. The growth of the market in Europe is due to rising healthcare expenditures and strategic developments by companies.
- Asia Pacific is expected to be the fastest-growing region for anti-epileptic drugs for pediatrics market, growing at a CAGR of 7.2% during the forecast period. The growth of the market in Asia Pacific is due to the improving healthcare infrastructure and expanding insurance coverage.
U.S.: 
U.K. : 
India : 
